Back
13 May 2026
The ITA confirms that athletes Gulsevar Urakova and Ozodbek Murotov have agreed¹ to the consequences imposed for their respective anti-doping rule violations (ADRVs) following positive results at the 2025 World Games held in Chengdu, China.
Ozodbek Murotov tested positive for the prohibited substance 19-norandrosterone after providing a sample on 12 August 2025 during an out-of-competition doping control at the 2025 World Games. 19-norandrosterone is prohibited under the WADA Prohibited List as S1.1 Anabolic Androgenic Steroids. 19-norandrosterone is prohibited at all times (in- and out-of-competition) and is a non-specified substance. 19-norandrosterone may boost athletic ability by increasing muscle strength and mass and accelerating recovery.
Gulsevar Urakova provided a sample during an out‑of‑competition doping control shortly before the 2025 World Games, which returned an adverse analytical finding (AAF)² for LGD‑4033 (ligandrol), RAD140 and enobosarm (ostarine). She also tested positive for the prohibited substances LGD‑4033 (ligandrol) and RAD140 after providing a sample on 14 August 2025 during an in‑competition doping control at the 2025 World Games. All these substances are selective androgen receptor modulators (SARMs) listed under the WADA Prohibited List as S1.2 Other Anabolic Agents. They are prohibited at all times and are classified as non-specified substances. SARMs are synthetic drugs that selectively stimulate androgen receptors, promoting muscle growth and enhancing physical performance.
On 16 December 2025, the ITA, on behalf of the International World Games Association (IWGA), issued a sanctioning decision against each athlete, holding they both had committed an ADRV for the presence and use of a prohibited substance and disqualified their respective results at the 2025 World Games. The athletes’ cases were then referred to the International Sambo Federation (FIAS) to determine the applicable consequences under the FIAS anti-doping rules.³
As a result, the athletes agreed with the consequences applicable under the FIAS anti-doping rules, namely:
Due to the early admission of their ADRVs, the athletes were entitled to a one-year reduction of the applicable periods of ineligibility as set forth in article 10.8.1 of the FIAS anti-doping rules.⁴
The ITA will not comment further on these cases.
¹ Athletes have the right to choose not to have their case referred to a hearing panel. In these instances, the anti-doping organisation will assess the athlete’s case file and establish the applicable consequences pursuant to the anti-doping rules and the athletes will have the right to accept the proposed consequences. If the athletes refuse the proposed consequences, their case is transferred to a hearing panel. This resolution mechanism is provided for in articles 8.3.1 and 8.3.3 of the IWGA anti-doping rules, articles 8.3.1 and 8.3.3 of the FIAS anti-doping rules and 8.3 of the World Anti-Doping Code, and is commonly referred to as an agreement on consequences. The athlete’s National Anti-Doping Organisation and the World Anti-Doping Agency have the right to appeal the agreement on consequences before the competent appeal body.
² A report from a WADA-accredited laboratory that, consistent with the International Standard for Laboratories, establishes in a Sample the presence of a Prohibited Substance or its Metabolites or Markers or evidence of the Use of a Prohibited Method.
³ According to Article 7.1.1 of the IWGA anti-doping rules, for an ADRV occurring during an IWGA event, IWGA shall refer the case to the applicable International Federation (here FIAS) for completion of results management.
⁴ Article 10.8.1 of the FIAS anti-doping rules (and World Anti-Doping Code) provides for a one-year reduction for certain ADRVs based on early admission and acceptance of sanction. This applies where an athlete after being notified of a potential ADRV that carries an asserted period of Ineligibility of four or more years, admits to the violation and accepts the asserted period of Ineligibility no later than within twenty (20) days after receiving a notice of charge.
